EFFECT OF MICRONIZED PURIFIED FLAVONOID FRACTION ON VENOUS HAEMODYNAMICS EVALUATED USING DIGITAL PHOTOPLETHYSMOGRAPHY IN PATIENTS WITH CHRONIC VENOUS DISEASE

Abstract

Micronized purified flavonoid fraction (MPFF) is the most widely prescribed and well-studied venoactive drug available for the treatment of chronic venous disease (CVD). Photoplethysmography (PPG) is used to quantitatively measure venous haemodynamics and provide information about the overall function of the venous system. The aim of this study was to use digital PPG to evaluate the effects of MPFF on venous haemodynamics in patients with CVD. Patients diagnosed with CVD at an outpatient clinic in Bursa, Turkey between February 2018 and July 2020 were assessed for inclusion in this retrospective analysis. Patients who complied with the advised treatment strategy (MPFF 1000 mg tablets taken orally once daily and compression garments) and attended follow-up visits were included in the analysis. Digital PPG was used to measure venous refilling time (VRT) and venous pumping capacity (VPC) at diagnosis and 6 months of follow-up. The Venous Clinical Severity Score (VCSS) was also obtained at these visits, and patients completed the 20-item Chronic Venous Insufficiency Quality of life Questionnaire (CIVIQ-20). In total, 721 patients (mean age 52 years) with C0-C4 CVD were included in the study. PPG showed that VRT and VPC increased significantly from 19.0 sec and 2.0%, respectively, at diagnosis to 27.4 and 4.9%, respectively, at 6 months (both p<0.05). Mean VCSS improved significantly from 7.9 at diagnosis to 3.1 at 6 months (p<0.05). Mean CIVIQ-20 score also improved significantly at the 6-month follow up (20.1 vs 38.6 at diagnosis; p<0.01). In patients with C0-C4 CVD, 6 months of MPFF treatment plus the wearing of compression garments was associated with statistically significant improvements in venous haemodynamic parameters measured by PPG, as well as measures of clinical severity and quality of life.